Artificial intelligence (AI) is a technology that takes over when the human brain has reached its limit. For medical technology companies, it could help in the creation of more precise tools and devices that support diagnostic, therapeutic and surgical decisions. Instead of shooting an arrow into the sky, the bullseye target is clear, backed up by volumes of data and a machine learning algorithm designed to pinpoint the biomarker, the abnormality and the probability of success.
As a cautious swimmer slips slowly into the cool waters of a giant swimming pool so do biopharma executives: They tread into the murky abyss known as artificial intelligence (AI).
Keeping with the trend of high-value biopharma deals, the second quarter of 2019 logged another eight partnerships worth $1 billion or more, with Gilead Sciences Inc. a party to three of them.
Keeping with the trend of high-value biopharma deals, the second quarter of 2019 logged another eight partnerships worth $1 billion or more, with Gilead Sciences Inc. a party to three of them.
Keeping with the trend of high-value biopharma deals, the second quarter of 2019 logged another eight partnerships worth $1 billion or more, with Gilead Sciences Inc. a party to three of them.
Public hearings, drafted recommendations and new legislation are all recent efforts by pain and addiction stakeholders, including government and industry, to effectively change standards of practice that have abandoned patients for years.
In a culture that dismisses pain and addiction as laziness or a moral failure, where drug developers find few economic incentives and patients hit treatment access roadblocks, those directly impacted are telling their stories to spur meaningful action.
PHILADELPHIA - While amounts raised through seed and series A venture capital rounds in 2018 have towered above previous years, indicating a growing interest in investing early, the money does not address a researcher's need to fund science at an even earlier stage, sometimes at the very beginnings of an idea.
